Curcumin and pomegrantes - new hope for Alzheimer’s prevention?
New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.
New research at the University of Warwick is underway to prove how well curcumin and pomegranates can hack autophagy to prevent Alzheimer’s disease.
The hope is that the studies will show that this naturally-occurring compounds found especially in turmeric can - when combined with intermittent fasting - prevent the build-up of damaging protein fragments that form between nerve cells in the brain and cause neurological problems.
It’s thought that these fragments may be produced as part of the brain’s self-defence process and that their presence is a symptom of the disease. In a healthy brain, these fragments are broken down and eliminated, but problems occur if they begin to accumulate and form the hard, insoluble amyloid plaques known to be one of the major symptoms of Alzheimer's disease.
Previous related research at the Chinese University of Hong Kong in 2008 found that Biocurcumax, a patented extract available as a food supplement, helped prevent further build-up of these amyloid plaques and subsequently was approved by the FDA for investigational Therapy.
The importance of curcumin seems to hinge on its ability to kick-start the cleansing process that otherwise can take up to eighteen hours of fasting for the body to begin by itself. The studies to date have shown that when curcumin is highly ‘bio-available’ - present in the bloodstream in potent amounts for a long-enough period of time – it can help autophagy start much sooner. Biocurcumax is a food supplement designed to allow active curcumin to be retained in the body for more than 8 hours.
Suphil Philipose, of BioTurm, the UK distributor of Biocurcumax says: "Research has already shown that highly bio-available curcumin, when combined with the essential oil of turmeric, can stop the progressive build-up of neurologically-damaging substances. This new research opens up a new world of hope to millions of people.”
Research conducted with the University of Rome in 2015 showed Biocurcumax was able to reverse the dysfunction that sometimes occurs in autophagy, the self-cleansing process.
New studies at the University of Warwick will now seek to show the actual extent to which curcumin and pomegranates can induce autophagy and remove the damaged cells. Should these prove successful, they will progress to a human clinical trial to demonstrate the efficacy of the solution.
Crucially curcumin is thought to also have a positive effect on apoptosis - the normal, controlled death of billions of cells in the adult body every day. Curcumin also restores and maintains a healthy mitochondria, the 'battery unit' of every cell.
Philipose adds: “Nature provides us with curcumin and pomegranates that can be used as hacks to induce and kick start the self-cleansing mechanism in the body. Adjunct to a fasting diet, we may have a pathway for preventing the disease.”
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance